Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

NCT07228832 is registered in ClinicalTrials.gov with Summit Therapeutics as lead sponsor.

NCT NCT07228832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07228832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer
Lead sponsor
Summit Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
November 18, 2025
Completion date
November 30, 2029
Enrollment
600 (estimated)
Sites
236

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (crc)